AR133266A1 - Macrociclos para el tratamiento de enfermedades autoinmunitarias - Google Patents
Macrociclos para el tratamiento de enfermedades autoinmunitariasInfo
- Publication number
- AR133266A1 AR133266A1 ARP240101844A ARP240101844A AR133266A1 AR 133266 A1 AR133266 A1 AR 133266A1 AR P240101844 A ARP240101844 A AR P240101844A AR P240101844 A ARP240101844 A AR P240101844A AR 133266 A1 AR133266 A1 AR 133266A1
- Authority
- AR
- Argentina
- Prior art keywords
- macrocycles
- treatment
- autoimmune diseases
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (1), en donde R¹ a R⁶, Q¹ y A¹ a A⁵ son como se describe en la presente, y su sal farmacéuticamente aceptable, y composiciones que incluyen los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023108207 | 2023-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133266A1 true AR133266A1 (es) | 2025-09-10 |
Family
ID=91966078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101844A AR133266A1 (es) | 2023-07-19 | 2024-07-16 | Macrociclos para el tratamiento de enfermedades autoinmunitarias |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4746963A1 (es) |
| JP (1) | JP2026525329A (es) |
| KR (1) | KR20260040007A (es) |
| CN (1) | CN121568945A (es) |
| AR (1) | AR133266A1 (es) |
| AU (1) | AU2024296084A1 (es) |
| CL (1) | CL2026000081A1 (es) |
| CO (1) | CO2026000531A2 (es) |
| IL (1) | IL324969A (es) |
| MX (1) | MX2026000537A (es) |
| PE (1) | PE20260753A1 (es) |
| TW (1) | TW202510858A (es) |
| WO (1) | WO2025017045A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250333398A1 (en) | 2024-04-30 | 2025-10-30 | Boehringer Ingelheim International Gmbh | Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228889A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228895A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament |
| WO2025228900A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Arylamide substituted indazoles and the use thereof as medicament |
| WO2025228899A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Further heterocyclic compounds as sting antagonists and the use thereof as medicament |
| WO2025228902A1 (en) | 2024-04-30 | 2025-11-06 | Boehringer Ingelheim International Gmbh | Heterocyclic acids as sting antagonists and the use thereof as medicament |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| KR20210146370A (ko) * | 2019-03-28 | 2021-12-03 | 루핀 리미티드 | Sting 효능제로서의 매크로사이클릭 화합물 |
| DK4004002T3 (da) * | 2019-07-22 | 2024-09-30 | Lupin Ltd | Makrocykliske forbindelser som sting-agonister samt fremgangsmåder og anvendelser dermed |
| IL314136A (en) * | 2022-02-02 | 2024-09-01 | Hoffmann La Roche | Imidazole macrocycles for the treatment of autoimmune disease |
-
2024
- 2024-07-16 AR ARP240101844A patent/AR133266A1/es unknown
- 2024-07-17 IL IL324969A patent/IL324969A/en unknown
- 2024-07-17 AU AU2024296084A patent/AU2024296084A1/en active Pending
- 2024-07-17 KR KR1020267002447A patent/KR20260040007A/ko active Pending
- 2024-07-17 JP JP2026502254A patent/JP2026525329A/ja active Pending
- 2024-07-17 CN CN202480046756.1A patent/CN121568945A/zh active Pending
- 2024-07-17 PE PE2026000077A patent/PE20260753A1/es unknown
- 2024-07-17 EP EP24746244.3A patent/EP4746963A1/en active Pending
- 2024-07-17 WO PCT/EP2024/070202 patent/WO2025017045A1/en not_active Ceased
- 2024-07-18 TW TW113126840A patent/TW202510858A/zh unknown
-
2026
- 2026-01-09 CL CL2026000081A patent/CL2026000081A1/es unknown
- 2026-01-14 MX MX2026000537A patent/MX2026000537A/es unknown
- 2026-01-19 CO CONC2026/0000531A patent/CO2026000531A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024296084A1 (en) | 2025-12-11 |
| KR20260040007A (ko) | 2026-03-23 |
| CO2026000531A2 (es) | 2026-02-02 |
| CN121568945A (zh) | 2026-02-24 |
| IL324969A (en) | 2026-01-01 |
| TW202510858A (zh) | 2025-03-16 |
| PE20260753A1 (es) | 2026-03-31 |
| CL2026000081A1 (es) | 2026-04-06 |
| JP2026525329A (ja) | 2026-07-29 |
| EP4746963A1 (en) | 2026-05-27 |
| WO2025017045A1 (en) | 2025-01-23 |
| MX2026000537A (es) | 2026-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| AR132340A1 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CO2025010435A2 (es) | Compuestos tricíclicos para el tratamiento de cáncer | |
| CO2025001184A2 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| CO2022010460A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| CO2024017733A2 (es) | Inhibidores macrocíclicos de kras para el tratamiento de cáncer | |
| AR133199A1 (es) | Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2024011088A2 (es) | Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias | |
| CL2021002621A1 (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria | |
| CO2026000531A2 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| MX2025002817A (es) | Compuestos para el tratamiento del cancer | |
| CL2024001635A1 (es) | Compuestos de diazaspiro sustituidos con carbonilo y su uso | |
| CO2025011377A2 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| AR128109A1 (es) | Spiros y análogos relacionados para inhibir yap / taz-tead | |
| CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
| CO2022006942A2 (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| AR133167A1 (es) | Macrociclos para el tratamiento de enfermedad autoinmunitaria | |
| CL2024000791A1 (es) | Compuestos de pirazolo[3,4-b]piridina para el tratamiento de enfermedades autoinmunitarias |